The global anticoagulant reversal drugs market size was worth around US$ 0.83 Billion in 2021 and is projected to grow around USD 2.25 Billion by 2030, with a compounded annual growth rate (CAGR) of roughly 11.27% from 2022 to 2030.
???? Click Here to access The Full market Report : https://www.zionmarketresearch.com/report/anticoagulant-reversal-drugs-market
➤ The market growth is driven by a substantial increase in the number of individuals experiencing bleeding disorders and abnormal blood coagulation.
The incidence of bleeding disorders has increased among individuals. Gastrointestinal (GI) hemorrhage is a prevalent condition that accounts for approximately 50% of primary bleeding events. Intracranial hemorrhage (ICH) is an additional significant condition that is becoming more common among patients who are prescribed DOACs (Direct-acting Oral Anticoagulants).
➤ The market’s expansion is impeded by the exorbitant cost of anticoagulant reversal medicines.
The market’s growth may be limited to some extent by the high cost of therapy and anticoagulant reversal drugs, which may not be affordable for patients who require these medications urgently but are unable to afford them. This could potentially lead to a decrease in the demand for these medications, particularly during the economic crisis that is currently affecting a number of countries.
➤ remunerative opportunities for market growth are presented by the increased adoption of new technologies and the development of novel medications.
Various countries worldwide are at the forefront of persistent technological advancements and improvements in healthcare infrastructure. This is primarily the result of exceptional research and development initiatives implemented by prominent companies to enhance and modernize laboratory clinics for a variety of drug discovery and testing procedures. The U.S. Centers for Medicare and Medicaid Services (CMS) have conferred the new technology add-on payment (NTAP) status to specific medications that are specifically engineered to interact with a limited number of anticoagulants.
➤ The market’s expansion may be hindered by specific adverse effects associated with drug administration.
The health of the individual, particularly among the geriatric population, can be adversely affected by the severe complications of excessive bleeding that can result from the application of certain medications. Consequently, the anticoagulant reversal medications industry may face a challenge in terms of growth due to the adverse side effects of the drugs.
???? Get more info : https://www.zionmarketresearch.com/buynow/su/anticoagulant-reversal-drugs-market
The Global Anticoagulant Reversal Drugs Market is segmented based on product, application and region
Global Anticoagulant Reversal Drugs Market: Product Segment Analysis
● Idarucizumab
● Protamine
● Prothrombin Complex Concentrates
● Coagulation Factors
● Phytonadione
● Andexanet Alfa
● Others
Global Anticoagulant Reversal Drugs Market: Application Segment Analysis
● Hospital
● Retail
● Online
Click on this Below Link to see Similar Reports :
https://www.linkedin.com/pulse/pharmaceutical-filtration-market-size-industry-p47nf/
https://www.linkedin.com/pulse/global-marinades-dressings-market-industry-mlzuf/
https://www.linkedin.com/pulse/potassium-citrate-market-share-size-industry-tq9of/
https://www.linkedin.com/pulse/global-povidone-iodine-market-analysis-drivers-cofsf
https://www.linkedin.com/pulse/anticoagulant-reversal-drugs-market-size-share-ua0mf/
https://www.linkedin.com/pulse/natural-language-processing-nlp-market-size-fqjnf/
The global Anticoagulant Reversal Drugs market profiles key players such as:
● Pfizer Inc.
● AstraZeneca
● Bristol-Myers Squibb Company
● Dr. Reddy’s Laboratories Ltd
● Endo International plc
● Teva Pharmaceutical Industries Ltd
● Sun Pharmaceutical Industries Ltd
● Mylan N.V.
● Novartis AG
● Lupin
● Cipla Inc
● Aurobindo Pharma
● Sanofi
● Merck & Co. Inc
???? Recent Developments:
• In March 2022, Ondexxya was the first reversal agent to be approved in Japan for patients who are receiving treatment with Factor Xa inhibitors rivaroxaban, apixaban, or edoxaban. In these cases, the reversal of anticoagulation is of the utmost significance due to lethal or immoderate bleeding. The Japanese Ministry of Health, Labour, and Welfare approved the drug in response to the remarkable conclusions drawn from the ANNEXA-4 Phase III clinical trial, which demonstrated that Ondexxya significantly reversed anti-FXa activity in patients who experienced lethal bleeding.
• A team led by Kirill Afonin, a researcher at UNC Charlotte, announced the launch of a new anticoagulant platform in July 2022. This platform has the potential to improve patient treatment during dialysis, cardiac surgeries, and other procedures.
➤ North America is expected to maintain its dominant position in the global market.
During the forecast period, the North American region is expected to experience exponential growth at a promising CAGR, and it held the largest market share in 2021. The primary reasons for the expansion of the anticoagulant reversal drugs market in this region are the increasing number of surgeries, the increase in the geriatric population, and the favorable approval of drugs for lethal bleeding disorders in the region.
???? Get Customization Report : https://www.zionmarketresearch.com/custom/6104
About Us :
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database.
Contact Us:
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714 USA/Canada Toll-Free No.1-855-465-4651
Email: [email protected]
Website: https://www.zionmarketresearch.com
Be First to Comment